الفهرس 
PlasminogenOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
The debate over the best thrornbolytic agent has engendered the largest clinical trials ever-undertaken, the Gissi-I1 (38) (Gmppo- Italino per Lo studio della seprawiwenza nell’ Infarc miocardico) study with its international extension and the recently published Isis- IIIW) trial (Thrid-International study of infarct survival ) ; these studies, of 20891 and 41299 patients respectively, have resolved most of the questions regarding the choice of the thrombolytic agents and the role of heparine.